Characteristics of the patients and clinical outcome
| Patient . | Sex (age in years) . | Diagnosis . | Disease status at SCT . | Conditioning/Intensity* . | Infused CD34/kg . | Infused CD3/kg . | Days from SCT to T-cell infusion . | Infused T cells/kg . | aGVHD . | cGVHD . | Administration of AP1903 . | Current status (day after SCT†) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M (3) | Secondary AML | CR2 | Bu-Flu-Campath/MAC | 1.2 × 107 | 8.2 × 104 | 66 | 1 × 106 | Grade I/II | None | Yes | Alive, CR (D+1440) |
| 2 | F (17) | B-ALL | CR2 | Bu-Cy-Campath/MAC | 1.0 × 107 | 3.8 × 104 | 80 and 111 | 1 × 106 | Grade I | None | Yes | Relapse of ALL (D+552), death D+591 |
| 3 | M (8) | T-ALL | PIF-CR1 | AraC-Cy-Campath- TBI/MAC | 1.3 × 107 | 1.7 × 105 | 93 | 3 × 106 | None | None | None | Alive, CR (D+1388) |
| 4 | F (4) | T-ALL | Active disease | Bu-Cy-Campath/MAC | 1.6 × 107 | 5.5 × 104 | 30 | 3 × 106 | Grade I | None | Yes | Relapse of ALL (D+57), death D+158 |
| 5 | M (6) | B-ALL | CR2 (7q31 del) | AraC-Cy-Campath-TBI/MAC | 1.5 × 107 | 0.4 × 104 | 42 | 1 × 107 | Grade I | None | Yes | Relapse of ALL (D+158), death D+164 |
| 6 | F (17) | Biphenotypic leukemia | CR2 | Flu-Mel-Campath/RIC | 0.8 × 107 | 0.3 × 104 | 87 | 1 × 106 | None | None | None | Alive, CR (D+1016) |
| 7 | F (7) | T-cell lymphoblastic lymphoma | CR2 | HDAC-Cy-Campath-TBI/cranial XRT/MAC | 1.3 × 107 | 0.9 × 104 | 75 and 368 | 1 × 107 | None | None | None | Alive, CR (D+954) |
| 8 | M (14) | T-ALCL | CR1 | AraC-Cy-Campath/MAC | 1.2 × 107 | 0.3 × 104 | 40 | 1 × 107 | None | None | None | Alive, CR (D+835) |
| 9 | F (9) | MDS monosomy 7 | No excess blasts | Flu-Campath-TBI/RIC | 2.2 × 107 | 0.5 × 104 | 90 and 271 | 1 × 107 1 × 106 | None | None | None | Relapse (D+312) alive, CR (D+475) (second allo-HSCT) |
| 10 | F (8) | Biphenotypic leukemia | CR1 | AraC-Cy-TBI/MAC | 1.5 × 107 | 0.6 × 104 | 124 and 248 | 1 × 107 5 × 106 | None | None | None | Death from respiratory failure secondary to refractory AIHA (D+ 615) |
| Patient . | Sex (age in years) . | Diagnosis . | Disease status at SCT . | Conditioning/Intensity* . | Infused CD34/kg . | Infused CD3/kg . | Days from SCT to T-cell infusion . | Infused T cells/kg . | aGVHD . | cGVHD . | Administration of AP1903 . | Current status (day after SCT†) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M (3) | Secondary AML | CR2 | Bu-Flu-Campath/MAC | 1.2 × 107 | 8.2 × 104 | 66 | 1 × 106 | Grade I/II | None | Yes | Alive, CR (D+1440) |
| 2 | F (17) | B-ALL | CR2 | Bu-Cy-Campath/MAC | 1.0 × 107 | 3.8 × 104 | 80 and 111 | 1 × 106 | Grade I | None | Yes | Relapse of ALL (D+552), death D+591 |
| 3 | M (8) | T-ALL | PIF-CR1 | AraC-Cy-Campath- TBI/MAC | 1.3 × 107 | 1.7 × 105 | 93 | 3 × 106 | None | None | None | Alive, CR (D+1388) |
| 4 | F (4) | T-ALL | Active disease | Bu-Cy-Campath/MAC | 1.6 × 107 | 5.5 × 104 | 30 | 3 × 106 | Grade I | None | Yes | Relapse of ALL (D+57), death D+158 |
| 5 | M (6) | B-ALL | CR2 (7q31 del) | AraC-Cy-Campath-TBI/MAC | 1.5 × 107 | 0.4 × 104 | 42 | 1 × 107 | Grade I | None | Yes | Relapse of ALL (D+158), death D+164 |
| 6 | F (17) | Biphenotypic leukemia | CR2 | Flu-Mel-Campath/RIC | 0.8 × 107 | 0.3 × 104 | 87 | 1 × 106 | None | None | None | Alive, CR (D+1016) |
| 7 | F (7) | T-cell lymphoblastic lymphoma | CR2 | HDAC-Cy-Campath-TBI/cranial XRT/MAC | 1.3 × 107 | 0.9 × 104 | 75 and 368 | 1 × 107 | None | None | None | Alive, CR (D+954) |
| 8 | M (14) | T-ALCL | CR1 | AraC-Cy-Campath/MAC | 1.2 × 107 | 0.3 × 104 | 40 | 1 × 107 | None | None | None | Alive, CR (D+835) |
| 9 | F (9) | MDS monosomy 7 | No excess blasts | Flu-Campath-TBI/RIC | 2.2 × 107 | 0.5 × 104 | 90 and 271 | 1 × 107 1 × 106 | None | None | None | Relapse (D+312) alive, CR (D+475) (second allo-HSCT) |
| 10 | F (8) | Biphenotypic leukemia | CR1 | AraC-Cy-TBI/MAC | 1.5 × 107 | 0.6 × 104 | 124 and 248 | 1 × 107 5 × 106 | None | None | None | Death from respiratory failure secondary to refractory AIHA (D+ 615) |
AIHA, autoimmune hemolytic anemia; ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; AraC, cytosine arabinoside; Bu, busulfan; CR, complete remission; Cy, cyclophosphamide; D, days; Flu, fludarabine; GvHD, graft versus host disease; HDAC, hyston decicetylase; HSCT, hematopoietic stem cell transplant; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; Mel, melphalan; PIF, primary induction failure; RIC, reduced intensity conditioning; SCT, stem cell transplant; TBI, total body irradiation; XRT, irradiation.
Intensity of conditioning classified according to Bacigalupo et al.25
Follow-up as of June 30, 2013.